CHICAGO, Jan. 17, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today commented on the high growth healthcare 3D printing market as the Company readies for its Regulation A+ equity crowdfunding offering. A recent report projects the global market to reach $2.2B by 2024.
The report states that the high growth and increased market opportunity will be driven by a higher number of surgeries and the rising demand for personalized medical care. In particular, increasing applications in tissue engineering and regenerative medicines will produce a major revenue generating segment, due specifically to the 3D printing of organs like liver and kidney, printing blood vessels and heart tissue, skin, cartilage, and bone – a segment geared directly toward BIOLIFE4D’s technology.
“The projected market growth is a positive sign for the industry as it continues to recognize the dire need for innovative technologies that can heal and save lives. As a company, we understand the unique opportunity in front of us to pioneer the 3D bioprinting industry and establish ourselves as a leader in the market,” said Steven Morris, CEO, BIOLIFE4D. “We have worked tirelessly to build a team of industry experts in both medicine and science, who share both our vision and enthusiasm for our Company mission. As this market growth is set to accelerate, we believe BIOLIFE4D is best positioned to develop pioneering 3D bioprinting technologies that can save countless lives, and to bring value back to our investors.”
The BIOLIFE4D bioprinted organ replacement process begins with a magnetic resonance imaging (MRI) procedure used to create a detailed three-dimensional image of a patient’s heart. Using this image, a computer software program will construct a digital model of a new heart for the patient, matching the shape and size of the original. Doctors safely take cells from the patient via a blood sample, and leveraging recent stem cell research breakthroughs, BIOLIFE4D plans to reprogram those blood cells and convert them to create specialized heart cells.
A “bio-ink” is created using the specialized heart cells combined with nutrients and other materials that will help the cells survive the bioprinting process. Bioprinting is done with a 3D bioprinter that is fed the dimensions obtained from the MRI. After printing, the heart is then matured in a bioreactor, conditioned to make it stronger and readied for patient transplant.
BIOLIFE4D has filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ equity crowdfunding rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. The “Reg A+” rules, outlined under the 2012 Jumpstart Our Business Startups (JOBS) Act, allow companies to raise up to $50 million in equity from non-accredited investors and others.
To see how BIOLIFE4D’s process starts with a patient’s own cells and ends with a functional human heart ready for transplant, please watch this video.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.
Although you are currently able to express your interest in investing, BIOLIFE4D Corporation is not yet accepting investments. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind.
FischTank Marketing and PR